Blood biomarkers for Alzheimer's disease and related disorders
Acta Neurologica Scandinavica · 2022-07 · 146 (1) · 51-55
DOI: 10.1111/ane.13628 ↗At a glance
Übersichtsarbeit in Acta Neurologica Scandinavica, published online on 2022-04-25. Written by Henrik Zetterberg and 1 co-authors. Institution: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölnd…. Major MEDLINE topics: Alzheimer Disease, Neurodegenerative Diseases. Cited 55 times so far (Crossref); 45 references. Funded by: the Swedish Research Council, the European Research Council, Swedish State Support for Clinical Research.
Topics: Demenz
Abstract (original language)
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause of dementia. Many other diseases can, however, cause dementia, and differential diagnosis can be challenging, especially in early disease stages. For most neurodegenerative dementias, accumulation of brain pathologies starts many years before clinical onset; the ability to detect these pathologies paves the way for targeted disease-modifying prevention trials. AD is associated with β-amyloid and tau pathologies, which can be quantified using cerebrospinal fluid and imaging biomarkers and, more recently, using highly sensitive blood tests. While for the most part, specific biomarkers of non-AD neurodegenerative dementias are lacking, non-specific biomarkers of neurodegeneration are available. This review summarizes recent advances in the neurodegenerative dementia blood biomarker research and discusses the next steps required for clinical implementation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
- UK Dementia Research Institute at UCL, London, UK.
- Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
- Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
ORCID profiles: Henrik Zetterberg
Funding
- the Swedish Research Council
- the European Research Council
- Swedish State Support for Clinical Research
- the Alzheimer Drug Discovery Foundation (ADDF), USA
- the AD Strategic Fund and the Alzheimer's Association
- the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
- the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE)
- the European Union Joint Programme-Neurodegenerative Disease Research
Cite
APA
Zetterberg, H., & Schott, J. M. (2022). Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurologica Scandinavica, 146(1), 51-55. https://doi.org/10.1111/ane.13628
Vancouver
Zetterberg H, Schott JM. Blood biomarkers for Alzheimer's disease and related disorders. Acta Neurologica Scandinavica. 2022;146(1):51-55. doi:10.1111/ane.13628
BibTeX
@article{Zetterberg2022,
author = {Zetterberg, Henrik and Schott, Jonathan M},
title = {Blood biomarkers for Alzheimer's disease and related disorders},
journal = {Acta Neurologica Scandinavica},
year = {2022},
volume = {146},
number = {1},
pages = {51--55},
doi = {10.1111/ane.13628}
}
EUVIMED